No Data
Express News | Amarin Published Data In Journal Of The American Heart Association Showing Post-Hoc Analysis Of REDUCE-IT Study Among Statin-Treated Patients With Elevated Triglycerides And High Cardiovascular Risk, VASCEPA/VAZKEPA
Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025
Tariffs Expected to Bring Pharmaceutical Price Bumps, Shortages -- Market Talk
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading
Amarin Corporation Announces National Reimbursement Approval for VAZKEPA in Italy to Reduce Cardiovascular Risk in High-Risk Patients
Executive Reshuffles: JPM, QCOM, DVN and LTC
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}